<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Amphastar P — News on 6ix</title>
    <link>https://6ix.com/company/amphastar-p</link>
    <description>Latest news and press releases for Amphastar P on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 26 Feb 2026 21:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/amphastar-p" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835460078dffbe2df0e2cbc.webp</url>
      <title>Amphastar P</title>
      <link>https://6ix.com/company/amphastar-p</link>
    </image>
    <item>
      <title>Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-ended-december-31-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-year-ended-december-31-2025</guid>
      <pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
      <description>Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025 GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or $2.03 per share, respectively, for the fourth ...</description>
    </item>
    <item>
      <title>Amphastar Announces FDA Approval for Ipratropium Bromide HFA</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-announces-fda-approval-for-ipratropium-bromide-hfa</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-announces-fda-approval-for-ipratropium-bromide-hfa</guid>
      <pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-call-on-february-26-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-call-on-february-26-2026</guid>
      <pubDate>Fri, 20 Feb 2026 05:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-announces-exclusive-license-agreement-nanjing-hanxin</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-announces-exclusive-license-agreement-nanjing-hanxin</guid>
      <pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
      <description>Agreement expands Amphastar&apos;s proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire /</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-present-jp-morgan-2026-healthcare-conference-2026-01-07</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-present-jp-morgan-2026-healthcare-conference-2026-01-07</guid>
      <pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President,</description>
    </item>
    <item>
      <title>Amphastar Announces FDA Approval for Teriparatide Injection</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-announces-fda-approval-teriparatide-injection-2025-12-15</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-announces-fda-approval-teriparatide-injection-2025-12-15</guid>
      <pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-present-37th-annual-piper-sandler-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-present-37th-annual-piper-sandler-healthcare-conference</guid>
      <pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-present-jefferies-global-healthcare-conference-2025-11-12</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-present-jefferies-global-healthcare-conference-2025-11-12</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-reports-financial-results-three-months-ended-september-30</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-reports-financial-results-three-months-ended-september-30</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-release-third-quarter-earnings-and-hold-conference-call</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-release-third-quarter-earnings-and-hold-conference-call</guid>
      <pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-present-2025-wells-fargo-healthcare-conference-2025-08-28</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-present-2025-wells-fargo-healthcare-conference-2025-08-28</guid>
      <pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-bolsters-proprietary-pipeline-through-exclusive-licensing</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-bolsters-proprietary-pipeline-through-exclusive-licensing</guid>
      <pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
      <description>Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August</description>
    </item>
    <item>
      <title>Amphastar Announces FDA Approval for Iron Sucrose Injection, USP</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-announces-fda-approval-iron-100000449</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-announces-fda-approval-iron-100000449</guid>
      <pubDate>Mon, 11 Aug 2025 10:00:00 GMT</pubDate>
      <description>According to the FDA, Amphastar&apos;s iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer ®for the treatment of iron deficiency anemia in patients with chronic kidney disease RANCHO CUCAMONGA, CA / ACCESS ...</description>
    </item>
    <item>
      <title>Amphastar Announces FDA Approval for Iron Sucrose Injection, USP </title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-announces-fda-approval-iron-sucrose-injection-usp-2025-08-11</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-announces-fda-approval-iron-sucrose-injection-usp-2025-08-11</guid>
      <pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
      <description>According to the FDA, Amphastar&apos;s iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-reports-financial-results-three-months-ended-june-30-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-reports-financial-results-three-months-ended-june-30-2025</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>- Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025- GAAP net income of $31.0 million, or $0.64 per share, for the second</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-release-second-quarter-earnings-and-hold-conference-call</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-release-second-quarter-earnings-and-hold-conference-call</guid>
      <pubDate>Tue, 29 Jul 2025 04:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-aims-quadruple-domestic-manufacturing-capacity-rancho</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-aims-quadruple-domestic-manufacturing-capacity-rancho</guid>
      <pubDate>Mon, 14 Jul 2025 04:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESS Newswire / July 14, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a bio-pharmaceutical company focused on developing,</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-present-2025-bank-america-health-care-conference-2025-05-09</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-present-2025-bank-america-health-care-conference-2025-05-09</guid>
      <pubDate>Fri, 09 May 2025 04:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner,</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-reports-financial-results-three-months-ended-march-31-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-reports-financial-results-three-months-ended-march-31-2025</guid>
      <pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
      <description>Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2025 / Amphastar</description>
    </item>
    <item>
      <title>Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025</title>
      <link>https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-release-first-quarter-earnings-and-hold-conference-call-may</link>
      <guid isPermaLink="true">https://6ix.com/company/amphastar-p/news/amphastar-pharmaceuticals-release-first-quarter-earnings-and-hold-conference-call-may</guid>
      <pubDate>Wed, 30 Apr 2025 04:00:00 GMT</pubDate>
      <description>RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for</description>
    </item>
  </channel>
</rss>